XML 197 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Basis of Presentation and Significant Accounting Policies - Additional Information (Details)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended 18 Months Ended
Jul. 30, 2019
USD ($)
$ / shares
Jul. 01, 2019
USD ($)
Jan. 01, 2019
USD ($)
Accounting_standard
Dec. 22, 2016
USD ($)
Nov. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Operating_Segment
Dec. 31, 2018
USD ($)
Operating_Segment
Dec. 31, 2017
USD ($)
Jul. 02, 2019
USD ($)
Jun. 28, 2020
Feb. 03, 2017
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Number of operating segments | Operating_Segment             3 2        
Number of accounting standards adopted | Accounting_standard     4                  
Cash payments for acquisition, net of cash acquired             $ 10,861 $ 0 $ 1,000      
ROU assets           $ 1,313 1,313          
Lease liabilities (long-term)           1,048 1,048          
Accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, cash discounts and sales returns           5,689 5,689 5,426        
Advertising expense             2,600 3,100 3,100      
Variable lease cost             328          
Array [Member]                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 48                      
Payments to acquire businesses, cash portion $ 11,200                      
Cash payments for acquisition, net of cash acquired $ 10,900                      
AstraZeneca [Member]                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Payments to acquire businesses, cash portion       $ 555         605      
Consideration transferred       $ 1,000                
ICU Medical [Member] | Disposed of by Sale, Not Discontinued Operations [Member] | HIS [Member]                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Cash received for disposition                       $ 900
Revenue [Member] | Top Eight Products [Member] | Product Concentration Risk [Member]                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Concentration risk, amount             $ 1,000          
Concentration risk, percentage             49.00%          
Revenue [Member] | Top Nine Products [Member] | Product Concentration Risk [Member]                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Concentration risk, amount                 $ 1,000      
Concentration risk, percentage                 46.00%      
Revenue [Member] | Top Ten Products [Member] | Product Concentration Risk [Member]                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Concentration risk, amount               $ 1,000        
Concentration risk, percentage               51.00%        
Accounting Standards Update 2016-02 [Member]                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
ROU assets     $ 1,400                  
Lease liabilities (long-term)     1,400                  
Cumulative effect on retained earnings, before tax     30                  
Cumulative effect on retained earnings, net of tax     $ 20                  
Research and Development Expense [Member] | Akcea And Ionis [Member] | Licensing Agreements [Member]                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Payment for licensing arrangement         $ 250 $ 250            
Therachon Asset Acquisition [Member]                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Upfront payment   $ 340                    
Maximum potential milestone payments   $ 470                    
Fair value of consideration transferred                   $ 322    
Minimum [Member]                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Operating lease term           1 year 1 year          
Operating lease term, option to extend             5 years          
Maximum [Member]                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Operating lease term           30 years 30 years          
Operating lease term, option to extend             10 years          
Forecast [Member] | Upjohn And Mylan [Member]                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Noncontrolling interest, ownership percentage by parent                     57.00%  
Forecast [Member] | Mylan [Member] | Upjohn And Mylan [Member]                        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                        
Noncontrolling interest, ownership percentage by noncontrolling owners                     43.00%